Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic...
Related Questions
How does the reported Q2 2025 revenue compare to consensus estimates and what is the variance?
What are the recent developments or trial results for Protalix’s lead product(s) and how might they affect future revenue?
What is the earnings per share (EPS) reported for Q2 2025 and how does it compare to analyst expectations?
What guidance did the company provide for Q3 2025 and full‑year 2025 revenue, earnings, and cash flow?
Did the company provide any updates on the FDA or other regulatory approvals for its pipeline products, especially any upcoming milestones?
How did the company's operating expenses and R&D spend change versus the prior quarter and year‑over‑year?
What is the current cash position and burn rate, and does the company have enough liquidity to fund its pipeline through 2027?
Did the company announce any new collaborations, licensing agreements, or partnership deals that could impact revenue or valuation?
How does Protalix’s valuation metrics (P/E, EV/EBITDA, price-to-sales) compare to peer companies in the recombinant therapeutic space?
What is the market’s reaction to the earnings release (stock price movement, volume) and what are the short‑term trade opportunities?
Are there any forward‑looking statements or risks highlighted that could affect the stock’s volatility in the next 30‑60 days?
What is the expected impact of the earnings release on the company's share buyback program or dividend policy, if any?